An innovative approach that could improve the efficacy of cancer immunotherapy
The immune system protects the human body against disease by destroying foreign substances such as bacteria and viruses. T lymphocytes, a type of white blood cell, are the active components in this process because they recognise and destroy foreign cells. By definition, cancer cells are not foreign cells and therefore are not likely to be recognised and attacked by the T lymphocytes. However, about thirty years ago, specific markers were discovered on the surface of cancer cells (called tumour antigens) that can be recognised by T cells that then destroy the cancerous cells. This work paved the way for cancer immunotherapy, a new treatment approach that helps T lymphocytes to destroy cancerous cells. Thanks to tumour specificity and the memory of these lymphocytes, immunotherapy makes it possible to treat advanced cancers with some success. It is now used worldwide. However, it is only effective in combating 30 to 40% of cancers. Indeed, many cancers are resistant, largely because their T lymphocytes are not sufficiently reactive.
New research by Benoit Van den Eynde's team (WEL Research Institute - UCLouvain) has revealed that drugs previously used to treat hypertension could have a very interesting effect in combating these forms of cancer that are resistant to immunotherapy.
These molecules have an effect on macrophages. Macrophages are another type of white blood cell, whose role is to engulf and digest debris from pathogens, such as cancer cells, microbes and foreign substances. They are, in a way, the human body’s waste collectors. However, while doing their job, these macrophages also alert the T lymphocytes of any abnormalities they encounter. They therefore act as sentinels: they raise the alarm and trigger the immune response.
Alongside their known hypotensive and anaesthetic effects, these molecules can also stimulate macrophages in their role as T-lymphocyte informants, making T lymphocytes more reactive and more effective at rejecting cancer cells, particularly in cancer models resistant to standard immunotherapy. This new approach could therefore “boost” the clinical immunotherapy process, particularly for the many cases of cancer for which this treatment is still of limited effectiveness.
These promising results call for additional research to find new molecules that might allow clinical trials to validate new treatments likely to offer enormous hope to patients suffering from cancers for which immunotherapy is currently not effective.
“One could imagine using existing blood pressure-lowering drugs,” explained Benoit Van den Eynde. “But it would be quite risky, owing to the undesired effects and the toxicity of these drugs at the necessary doses. Another approach is to develop new molecules that would act in the same way on macrophages, but would not have the unwanted toxic effects. We have already made significant progress in this direction.”
Reference : Zhu et al (2023) Nature https://doi.org/10.1038/s41586-023-06110-8
Source : Press release UCLouvain